Business Description
Cengild Medical Bhd
ISIN : MYQ0243OO004
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 11 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | 0.4 | |||||
Interest Coverage | 19.61 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 7.94 | |||||
Beneish M-Score | -2.01 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.8 | |||||
3-Year EBITDA Growth Rate | 1.4 | |||||
3-Year EPS without NRI Growth Rate | 2.7 | |||||
3-Year Book Growth Rate | 98.5 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 19.47 | |||||
9-Day RSI | 23.67 | |||||
14-Day RSI | 27.36 | |||||
6-1 Month Momentum % | -10 | |||||
12-1 Month Momentum % | -18.18 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.73 | |||||
Quick Ratio | 6.62 | |||||
Cash Ratio | 6.06 | |||||
Days Inventory | 17.38 | |||||
Days Sales Outstanding | 30.51 | |||||
Days Payable | 33.28 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 3.08 | |||||
Dividend Payout Ratio | 0.57 | |||||
Forward Dividend Yield % | 3.08 | |||||
5-Year Yield-on-Cost % | 2.96 | |||||
3-Year Average Share Buyback Ratio | -0.6 | |||||
Shareholder Yield % | 4.21 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 46.51 | |||||
Operating Margin % | 18.45 | |||||
Net Margin % | 16.57 | |||||
FCF Margin % | -4.19 | |||||
ROE % | 10.19 | |||||
ROA % | 8.24 | |||||
ROIC % | 26.4 | |||||
3-Year ROIIC % | -115.33 | |||||
ROC (Joel Greenblatt) % | 65.77 | |||||
ROCE % | 13.62 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 17.48 | |||||
PE Ratio without NRI | 17.48 | |||||
Price-to-Owner-Earnings | 18.1 | |||||
PEG Ratio | 0.78 | |||||
PS Ratio | 3.1 | |||||
PB Ratio | 1.84 | |||||
Price-to-Tangible-Book | 1.85 | |||||
Price-to-Operating-Cash-Flow | 16.32 | |||||
EV-to-EBIT | 7.43 | |||||
EV-to-EBITDA | 5.98 | |||||
EV-to-Revenue | 1.83 | |||||
EV-to-FCF | -46.82 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.83 | |||||
Price-to-Graham-Number | 1.2 | |||||
Price-to-Net-Current-Asset-Value | 2.67 | |||||
Price-to-Net-Cash | 3 | |||||
Earnings Yield (Greenblatt) % | 13.46 | |||||
FCF Yield % | -1.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Cengild Medical Bhd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil RM) | 66.854 | ||
EPS (TTM) (RM) | 0.014 | ||
Beta | 0 | ||
Volatility % | 18.11 | ||
14-Day RSI | 27.36 | ||
14-Day ATR (RM) | 0.007641 | ||
20-Day SMA (RM) | 0.25925 | ||
12-1 Month Momentum % | -18.18 | ||
52-Week Range (RM) | 0.24 - 0.35 | ||
Shares Outstanding (Mil) | 832.91 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cengild Medical Bhd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Cengild Medical Bhd Stock Events
Event | Date | Price(RM) | ||
---|---|---|---|---|
No Event Data |
Cengild Medical Bhd Frequently Asked Questions
What is Cengild Medical Bhd(XKLS:0243)'s stock price today?
When is next earnings date of Cengild Medical Bhd(XKLS:0243)?
Does Cengild Medical Bhd(XKLS:0243) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |